IPO registrations (S-1, F-1) · Underwriters
Laidlaw & Company
- Deals
- 21 priced offerings as an underwriter, 13 as lead manager or representative; 18 initial public offerings
- Proceeds of those deals
- $274,493,073 ($114,134,813 as lead)
- Years
- 1996–2026
- Named in
- 39 prospectuses and registration statements in all, including offerings not yet priced or withdrawn
Deals by year
| Year | Deals | As lead | Proceeds of deals |
|---|---|---|---|
| 2026 | 1 | 0 | $502,501 |
| 2025 | 1 | 1 | $10,000,000 |
| 2024 | 1 | 0 | $8,004,000 |
| 2023 | 1 | 1 | $7,000,000 |
| 2022 | 1 | 1 | $5,000,000 |
| 2021 | 1 | 0 | $24,999,996 |
| 2020 | 1 | 1 | $15,000,000 |
| 2019 | 1 | 1 | $6,250,000 |
| 2018 | 3 | 1 | $52,134,809 |
| 2017 | 1 | 1 | $12,000,000 |
| 2016 | 3 | 2 | $52,500,000 |
| 2015 | 2 | 1 | $50,000,000 |
| 2014 | 1 | 1 | $8,000,004 |
| 2013 | 1 | 0 | $23,101,763 |
| 1998 | 1 | 1 | - |
| 1996 | 1 | 1 | - |
Deals 21
| Priced | Company | Role | Price | Range | Shares | Proceeds | Listing | Kind | Syndicate | Prospectus |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | CURIS INC MA | Syndicate | $1.50 | 335,001 | $502,501 | Nasdaq CRIS | Offering | 2 | 424B4 ↗ | |
| 2025-08-14 | Nasus Pharma Ltd L3 | Lead | $8.00 | 1,250,000 | $10,000,000 | NYSE American NSRX | IPO | 3 | 424B4 ↗ | |
| 2024-02-09 | Perfect Moment Ltd. NY | Syndicate | $6.00 | 1,334,000 | $8,004,000 | NYSE American PMNT | IPO | 2 | 424B4 ↗ | |
| 2023-02-16 | GAXOS.AI INC. NJ | Lead | $4.15 | 1,686,747 | $7,000,000 | Nasdaq NFTG | IPO | 2 | 424B4 ↗ | |
| 2022-09-28 | Silo Pharma, Inc. FL | Lead | $5.00 | 1,000,000 | $5,000,000 | Nasdaq SILO | Offering | 1 | 424B4 ↗ | |
| 2021-12-09 | Cingulate Inc. KS | Syndicate | $6.00 | 4,166,666 | $24,999,996 | Nasdaq CING | IPO | 3 | 424B4 ↗ | |
| 2020-09-28 | Amesite Inc. MI | Lead | $5.00 | 3,000,000 | $15,000,000 | Nasdaq AMST | IPO | 2 | 424B4 ↗ | |
| 2019-02-15 | Rocket One Inc. NJ | Lead | $5.00 | 1,250,000 | $6,250,000 | Nasdaq HOTH | IPO | 1 | 424B4 ↗ | |
| 2018-11-26 | Taiwan Liposome Company, Ltd. F5 | Syndicate | $5.80 | 3,750,000 | $21,750,000 | Nasdaq TLC | IPO | 5 | 424B4 ↗ | |
| 2018-11-21 | Tiziana Life Sciences Ltd X0 | Lead | $9.90 | 442,910 | $4,384,809 | Nasdaq TLSA | IPO | 1 | 424B4 ↗ | |
| 2018-08-15 | Aridis Pharmaceuticals, Inc. CA | Syndicate | $13.00 | 2,000,000 | $26,000,000 | Nasdaq ARDS | IPO | 5 | 424B4 ↗ | |
| 2017-03-22 | SciSparc Ltd. L3 | Lead | $6.00 | 2,000,000 | $12,000,000 | OTC THXBY | IPO | 2 | 424B4 ↗ | |
| 2016-09-19 | TOWERSTREAM CORP RI | Lead | $1.35 | 2,962,963 | $4,000,000 | Nasdaq TWER | Offering | 1 | 424B4 ↗ | |
| 2016-08-08 | MetaVia Inc. MA | Syndicate | $10.00 | 3,000,000 | $30,000,000 | Nasdaq GEMP | IPO | 5 | 424B4 ↗ | |
| 2016-05-18 | PHASERX, INC. WA | Lead | $5.00 | 3,700,000 | $18,500,000 | Nasdaq PZRX | IPO | 2 | 424B4 ↗ | |
| 2015-10-15 | Avalo Therapeutics, Inc. PA | Syndicate | $6.49 | 4,000,000 | $26,000,000 | Nasdaq CERC | IPO | 2 | 424B4 ↗ | |
| 2015-04-29 | Viking Therapeutics, Inc. CA | Lead | $8.00 | 3,000,000 | $24,000,000 | Nasdaq VKTX | IPO | 2 | 424B4 ↗ | |
| 2014-12-19 | Innoveren Scientific, Inc. OH | Lead | $5.75 | 1,391,305 | $8,000,004 | Nasdaq MDVX | IPO | 1 | 424B4 ↗ | |
| 2013-10-17 | ADMA BIOLOGICS, INC. NJ | Syndicate | $6.89 | 3,352,941 | $23,101,763 | OTCQB ADMA | IPO | 4 | 424B4 ↗ | |
| 1998-03-13 | TOUSA INC FL | Lead | 2,000,000 | - | Nasdaq NHCH | IPO | 15 | 424B4 ↗ | ||
| 1996-10-16 | METROGOLF INC CO | Lead | 1,175,000 | - | Nasdaq MGLF | IPO | 15 | 424B1 ↗ |
“Offering” is a priced registered offering that the cover page does not describe as an initial public offering: a follow-on, a resale, or a small company’s best-efforts deal.
Registrations in progress or never priced 1
| Filed | Company | Role | Range | Shares | Listing | Status | Document |
|---|---|---|---|---|---|---|---|
| 1998-02-17 | TOUSA INC | Lead | $9.00–$11.00 | 2,000,000 | Nasdaq NHCH | Priced 1998-03-13 (terms not read) | S-1/A ↗ |
Works alongside
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Offering terms are read from the cover pages of the registrant's final prospectus (424B4, 424B1) and its latest registration statement before pricing: the price range, the final price, shares offered, gross proceeds (the cover's total, else price times shares), exchange and ticker, and the underwriters named on the cover and in the underwriting table (loader/s1_terms.py). Underwriter names are normalised, so Goldman, Sachs & Co. of 1999 and Goldman Sachs & Co. LLC of 2024 are one firm.